Compositions and methods of increasing longevity or treating cellular stress
AssigneeYale University
InventorsLaura E. NIKLASON, Xiangru XU, Hong QIAN
Life of this patent
Estimating the term…
Abstract
The present invention includes methods and compositions for increasing longevity of a cell and increasing cellular resistance to stress. In certain embodiments, the invention includes a method to induce gene expression of a homolog of Pachytene Checkpoint 2 (pch-2) or bmk-1 gene. The present invention also includes methods to treat oxidative stress or induce cellular death or apoptosis by administering a composition comprising a modulator of pch-2 or bmk-1 homolog gene expression.
Claims34
A method for increasing longevity of a cell or organism comprising administering to the cell or organism a composition that induces expression of at least one homolog selected from the group consisting of Pachytene Checkpoint 2 (PCH-2), BMK-1, Thyroid receptor-interacting, protein 13 (TRIP13) and kinesin KIF11.
A method for increasing cellular resistance to stress, aging or DNA damage in a cell comprising contacting the cell with a composition that induces expression of at least one homolog selected from the group consisting of Pachytene Checkpoint 2 (PCH-2), BMK-1, Thyroid receptor-interacting protein 13 (TRIP13) and kinesin KIF11.
(canceled)
(canceled)
A method for increasing longevity of a cell or organism comprising administering a composition comprising a homolog selected from the group consisting of Pachytene Checkpoint 2 (PCH-2) and BMK-1.
A method for increasing cellular resistance to stress, aging or DNA damage in a cell comprising contacting the cell with a composition comprising a homolog selected from the group consisting of Pachytene Checkpoint 2 (PCH-2) and BMK-1.
A method of treating a condition associated with oxidative stress, aging or DNA damage in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid encoding a homolog, or a modulator of a homolog wherein the homolog is selected from the group consisting of Pachytene Checkpoint 2 (PCH-2), BMK-1, Thyroid receptor-interacting protein 13 (TRIP13) and kinesin KIF11.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of inducing cell death comprising administering a composition that inhibits expression of a homolog selected from the group consisting of Pachytene Checkpoint 2 (pch-2), BMK-1, Thyroid receptor-interacting protein 13 (TRIP13) and kinesin KIF11.
A method of decreasing longevity of a cell comprising administering a composition that inhibits expression of a homolog selected from the group consisting of Pachytene Checkpoint 2 (pch-2), BMK-1, Thyroid receptor-interacting protein 13 (TRIP13) and kinesin KIF11.
(canceled)
(canceled)
Dependencies are inferred from the claim text.